Cargando…
Evaluation of a recombination-resistant coronavirus as a broadly applicable, rapidly implementable vaccine platform
Emerging and re-emerging zoonotic viral diseases are major threats to global health, economic stability, and national security. Vaccines are key for reducing coronaviral disease burden; however, the utility of live-attenuated vaccines is limited by risks of reversion or repair. Because of their hist...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206136/ https://www.ncbi.nlm.nih.gov/pubmed/30393776 http://dx.doi.org/10.1038/s42003-018-0175-7 |
_version_ | 1783366309238538240 |
---|---|
author | Graham, Rachel L. Deming, Damon J. Deming, Meagan E. Yount, Boyd L. Baric, Ralph S. |
author_facet | Graham, Rachel L. Deming, Damon J. Deming, Meagan E. Yount, Boyd L. Baric, Ralph S. |
author_sort | Graham, Rachel L. |
collection | PubMed |
description | Emerging and re-emerging zoonotic viral diseases are major threats to global health, economic stability, and national security. Vaccines are key for reducing coronaviral disease burden; however, the utility of live-attenuated vaccines is limited by risks of reversion or repair. Because of their history of emergence events due to their prevalence in zoonotic pools, designing live-attenuated coronavirus vaccines that can be rapidly and broadly implemented is essential for outbreak preparedness. Here, we show that coronaviruses with completely rewired transcription regulatory networks (TRNs) are effective vaccines against SARS-CoV. The TRN-rewired viruses are attenuated and protect against lethal SARS-CoV challenge. While a 3-nt rewired TRN reverts via second-site mutation upon serial passage, a 7-nt rewired TRN is more stable, suggesting that a more extensively rewired TRN might be essential for avoiding growth selection. In summary, rewiring the TRN is a feasible strategy for limiting reversion in an effective live-attenuated coronavirus vaccine candidate that is potentially portable across the Nidovirales order. |
format | Online Article Text |
id | pubmed-6206136 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-62061362018-11-02 Evaluation of a recombination-resistant coronavirus as a broadly applicable, rapidly implementable vaccine platform Graham, Rachel L. Deming, Damon J. Deming, Meagan E. Yount, Boyd L. Baric, Ralph S. Commun Biol Article Emerging and re-emerging zoonotic viral diseases are major threats to global health, economic stability, and national security. Vaccines are key for reducing coronaviral disease burden; however, the utility of live-attenuated vaccines is limited by risks of reversion or repair. Because of their history of emergence events due to their prevalence in zoonotic pools, designing live-attenuated coronavirus vaccines that can be rapidly and broadly implemented is essential for outbreak preparedness. Here, we show that coronaviruses with completely rewired transcription regulatory networks (TRNs) are effective vaccines against SARS-CoV. The TRN-rewired viruses are attenuated and protect against lethal SARS-CoV challenge. While a 3-nt rewired TRN reverts via second-site mutation upon serial passage, a 7-nt rewired TRN is more stable, suggesting that a more extensively rewired TRN might be essential for avoiding growth selection. In summary, rewiring the TRN is a feasible strategy for limiting reversion in an effective live-attenuated coronavirus vaccine candidate that is potentially portable across the Nidovirales order. Nature Publishing Group UK 2018-10-29 /pmc/articles/PMC6206136/ /pubmed/30393776 http://dx.doi.org/10.1038/s42003-018-0175-7 Text en © The Author(s) 2018 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Article Graham, Rachel L. Deming, Damon J. Deming, Meagan E. Yount, Boyd L. Baric, Ralph S. Evaluation of a recombination-resistant coronavirus as a broadly applicable, rapidly implementable vaccine platform |
title | Evaluation of a recombination-resistant coronavirus as a broadly applicable, rapidly implementable vaccine platform |
title_full | Evaluation of a recombination-resistant coronavirus as a broadly applicable, rapidly implementable vaccine platform |
title_fullStr | Evaluation of a recombination-resistant coronavirus as a broadly applicable, rapidly implementable vaccine platform |
title_full_unstemmed | Evaluation of a recombination-resistant coronavirus as a broadly applicable, rapidly implementable vaccine platform |
title_short | Evaluation of a recombination-resistant coronavirus as a broadly applicable, rapidly implementable vaccine platform |
title_sort | evaluation of a recombination-resistant coronavirus as a broadly applicable, rapidly implementable vaccine platform |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206136/ https://www.ncbi.nlm.nih.gov/pubmed/30393776 http://dx.doi.org/10.1038/s42003-018-0175-7 |
work_keys_str_mv | AT grahamrachell evaluationofarecombinationresistantcoronavirusasabroadlyapplicablerapidlyimplementablevaccineplatform AT demingdamonj evaluationofarecombinationresistantcoronavirusasabroadlyapplicablerapidlyimplementablevaccineplatform AT demingmeagane evaluationofarecombinationresistantcoronavirusasabroadlyapplicablerapidlyimplementablevaccineplatform AT yountboydl evaluationofarecombinationresistantcoronavirusasabroadlyapplicablerapidlyimplementablevaccineplatform AT baricralphs evaluationofarecombinationresistantcoronavirusasabroadlyapplicablerapidlyimplementablevaccineplatform |